Pfizer Shares Dipped Following Release of Phase III Palbociclib Study Data

Pfizer Shares Dipped Following Release of Phase III Palbociclib Study Data

Source: 
BioSpace
snippet: 

Pfizer shared results from its collaborative Phase III Palbociclib Collaborative Adjuvant Study (PALLAS) on Friday, and the data determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival in patients with breast cancer. As a result, shares of the company fell 6% in after-market trading, according to Yahoo! Finance.